Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics

Proteomics

Volumn 11, Issue 24, 2011, Pages 4677-4687

  Tian, Yuan ^a   Yao, Zhihao ^b   Roden, Richard B S ^a   Zhang, Hui ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Merck Serono   (China)

Author keywords

Histological subtypes; MS; Ovarian tumor; Quantitative glycoproteomics; Western blot

Indexed keywords

ACID CERAMIDASE; ADIPOCYTE PLASMA MEMBRANE ASSOCIATED PROTEIN; ALPHA INTEGRIN; ANGIOTENSIN CONVERTING ENZYME LIKE PROTEIN; BA209J19.1.1 PROTEIN; BETA2 INTEGRIN; BILIARY GLYCOPROTEIN; CARBOXYPEPTIDASE C; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 5; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CATHEPSIN D; CERULOPLASMIN; CLUSTERIN; DESMOGLEIN 2; GLYCOPROTEIN; GPR107 PROTEIN; HERMES ANTIGEN; HYPOTHETICAL PROTEIN MGC44287; LUTHERAN BLOOD GROUP GLYCOPROTEIN; MESOTHELIN; MUCIN 2; MUCIN 5B; MYELOPEROXIDASE; NECTIN 1; OXYGEN REGULATED PROTEIN 150; TENASCIN; TETRASPANIN; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERSICAN;

ARTICLE; CLEAR CELL CARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MUCINOUS CARCINOMA; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE GLYCOPROTEOMIC ANALYSIS; SEROUS CARCINOMA; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; WESTERN BLOTTING;

CARCINOEMBRYONIC ANTIGEN; FEMALE; GLYCOPROTEINS; GPI-LINKED PROTEINS; HUMANS; OVARIAN NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 82955161671     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000811     Document Type: Article

References (48)

1. Christie, M., Oehler, M. K., Molecular pathology of epithelial ovarian cancer. J. Br. Menopause Soc. 2006, 12, 57-63.
2. Einhorn, N., Trope, C., Ridderheim, M., Boman, K. et al., A systematic overview of radiation therapy effects in ovarian cancer. Acta Oncol. 2003, 42, 562-566.
3. Zhu, Y., Wu, R., Sangha, N., Yoo, C. et al., Classifications of ovarian cancer tissues by proteomic patterns. Proteomics 2006, 6, 5846-5856.
4. Jaffe, N. S., Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues, Lyon: International Agency for Research in Cancer 2003.
5. Seidman, J., Russell, P., Kurman, R. J., Surface epithelial tumors of the ovary. In: Kurman, R. J, (ed). Blaustein's Pathology of the Female Genital Tract (5th Eedn), Springer, New York 2002.
6. du Bois, A., Luck, H. J., Meier, W., Adams, H. P. et al., A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 2003, 95, 1320-1329.
7. Biade, S., Marinucci, M., Schick, J., Roberts, D. et al., Gene expression profiling of human ovarian tumours. Br. J. Cancer 2006, 95, 1092-1100.
8. Seidman, J. D., Horkayne-Szakaly, I., Haiba, M., Boice, C. R. et al., The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int. J. Gynecol. Pathol. 2004, 23, 41-44.
9. McGuire, V., Jesser, C. A., Whittemore, A. S., Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol. Oncol. 2002, 84, 399-403.
10. Schmandt, R. E., Bennett, M., Clifford, S., Thornton, A. et al., The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol. Ther. 2006, 5, 1136-1141.
11. Sugiyama, T., Kamura, T., Kigawa, J., Terakawa, N. et al., Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000, 88, 2584-2589.
12. Itamochi, H., Kigawa, J., Sultana, H., Iba, T. et al., Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn. J. Cancer Res. 2002, 93, 723-728.
13. Goff, B. A., Sainz de la Cuesta, R., Muntz, H. G., Fleischhacker, D. et al., Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol. Oncol. 1996, 60, 412-417.
14. Singer, G., Kurman, R. J., Chang, H. W., Cho, S. K., Shih Ie, M., Diverse tumorigenic pathways in ovarian serous carcinoma. Am. J. Pathol. 2002, 160, 1223-1228.
15. Singer, G., Stohr, R., Cope, L., Dehari, R. et al., Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am. J. Surg. Pathol. 2005, 29, 218-224.
16. Aunoble, B., Sanches, R., Didier, E., Bignon, Y. J., Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int. J. Oncol. 2000, 16, 567-576.
17. Feeley, K. M., Wells, M., Precursor lesions of ovarian epithelial malignancy. Histopathology 2001, 38, 87-95.
18. Zhang, H., Li, X. J., Martin, D. B., Aebersold, R., Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat. Biotechnol. 2003, 21, 660-666.
19. Tian, Y., Zhou, Y., Elliott, S., Aebersold, R., Zhang, H., Solid-phase extraction of N-linked glycopeptides. Nat. Protoc. 2007, 2, 334-339.
20. Pedrioli, P. G., Eng, J. K., Hubley, R., Vogelzang, M. et al., A common open representation of mass spectrometry data and its application to proteomics research. Nat. Biotechnol. 2004, 22, 1459-1466.
21. Eng, J., McCormack, A. L., Yates, J. R., III, An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J. Am. Soc. Mass Spectrom. 1994, 5, 976-989.
22. Keller, A., Nesvizhskii, A. I., Kolker, E., Aebersold, R., Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 2002, 74, 5383-5392.
23. Nesvizhskii, A. I., Keller, A., Kolker, E., Aebersold, R., A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 2003, 75, 4646-4658.
24. Zhang, H., Loriaux, P., Eng, J., Campbell, D. et al., UniPep - a database for human N-linked glycosites: a resource for biomarker discovery. Genome Biol. 2006, 7, R73.
25. Nielsen, H., Engelbrecht, J., Brunak, S., von Heijne, G., A neural network method for identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Int. J. Neural Syst. 1997, 8, 581-599.
26. Krogh, A., Larsson, B., von Heijne, G., Sonnhammer, E. L., Predicting transmembrane protein topology with a hidden Markov model: Application to complete genomes. J. Mol. Biol. 2001, 305, 567-580.
27. Liu, H., Sadygov, R. G., Yates III, J. R., A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem. 2004, 76, 4193-4201.
28. Tian, Y., Tan, A., Sun, X., Olson, M. T., Xie, Z., Jinawath, N., Chan, D. W., Shih Ie, M., Zhang, Z., and Zhang, H., Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with paclitaxel resistance proteomics. Proteomics Clin. Appl. 2009, 3, 1288-1295.
29. Neilson, K. A., Ali, N. A., Muralidharan, S., Mirzaei, M. et al., Less label, more free: approaches in label-free quantitative mass spectrometry. Proteomics 2011, 11, 535-553.
30. Ordonez, N. G., Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod. Pathol. 2003, 16, 192-197.
31. Frierson, H. F., Jr., Moskaluk, C. A., Powell, S. M., Zhang, H. et al., Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum. Pathol. 2003, 34, 605-609.
32. Schaner, M. E., Ross, D. T., Ciaravino, G., Sorlie, T. et al., Gene expression patterns in ovarian carcinomas. Mol. Biol. Cell 2003, 14, 4376-4386.
33. Sato, N., Fukushima, N., Maitra, A., Iacobuzio-Donahue, C. A. et al., Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am. J. Pathol. 2004, 164, 903-914.
34. Argani, P., Iacobuzio-Donahue, C., Ryu, B., Rosty, C. et al., Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res. 2001, 7, 3862-3868.
35. Antonescu, C. R., Viale, A., Sarran, L., Tschernyavsky, S. J. et al., Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin. Cancer Res. 2004, 10, 3282-3290.
36. Robinson, B. W., Creaney, J., Lake, R., Nowak, A. et al., Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003, 362, 1612-1616.
37. Swierczynski, S. L., Maitra, A., Abraham, S. C., Iacobuzio-Donahue, C. A. et al., Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum. Pathol. 2004, 35, 357-366.
38. Ordonez, N. G., Application of mesothelin immunostaining in tumor diagnosis. Am. J. Surg. Pathol. 2003, 27, 1418-1428.
39. Yen, M. J., Hsu, C. Y., Mao, T. L., Wu, T. C. et al., Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin. Cancer Res. 2006, 12, 827-831.
40. Yoshioka, T., Masuko, T., Kotanagi, H., Aizawa, O. et al., Homotypic adhesion through carcinoembryonic antigen plays a role in hepatic metastasis development. Jpn. J. Cancer Res. 1998, 89, 177-185.
41. Thomas, P., Gangopadhyay, A., Steele, G., Jr., Andrews, C. et al., The effect of transfection of the CEA gene on the metastatic behavior of the human colorectal cancer cell line MIP-101. Cancer Lett. 1995, 92, 59-66.
42. Blumenthal, R. D., Hansen, H. J., Goldenberg, D. M., Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Cancer Res. 2005, 65, 8809-8817.
43. Gold, P., Freedman, S. O., Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J. Exp. Med. 1965, 121, 439-462.
44. Kim, D. Y., Kim, H. R., Shim, J. H., Park, C. S. et al., Significance of serum and tissue carcinoembryonic antigen for the prognosis of gastric carcinoma patients. J. Surg. Oncol. 2000, 74, 185-192.
45. Scholzel, S., Zimmermann, W., Schwarzkopf, G., Grunert, F. et al., Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas. Am. J. Pathol. 2000, 156, 595-605.
46. Hinoda, Y., Saito, T., Takahashi, H., Itoh, F. et al., Induction of nonspecific cross-reacting antigen mRNA by interferon-gamma and anti-fibronectin receptor antibody in colon cancer cells. J. Gastroenterol. 1997, 32, 200-205.
47. Kuroki, M., Matsushita, H., Matsumoto, H., Hirose, Y. et al., Nonspecific cross-reacting antigen-50/90 (NCA-50/90) as a new tumor marker. Anticancer Res. 1999, 19, 5599-5606.
48. Blumenthal, R. D., Leon, E., Hansen, H. J., Goldenberg, D. M., Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer 2007, 7, 2.